IZUMO2 and acute myeloid leukemia: scRL’s superior performance across diverse biological systems—including human hematopoiesis, acute myeloid leukemia, mouse endocrinogenesis and perturbation studies—demonstrates its versatility in capturing early decision states that conventional methods fail to detect.